Publicaciones en las que colabora con David Díaz Valle (10)

2023

  1. Correction to: Validation of UVEDAI: An Index for Evaluating the Level of Inflammatory Activity in Uveitis (Ophthalmology and Therapy, (2023), 12, 2, (1045-1055), 10.1007/s40123-023-00654-8)

    Ophthalmology and Therapy

  2. SER recommendations for the treatment of uveitis

    Reumatologia Clinica, Vol. 19, Núm. 9, pp. 465-477

  3. Validation of UVEDAI: An Index for Evaluating the Level of Inflammatory Activity in Uveitis

    Ophthalmology and Therapy, Vol. 12, Núm. 2, pp. 1045-1055

2021

  1. Inflammatory Relapses after Immunosuppressive Drug Discontinuation in Uveitis Patients: A Survival Analysis

    Ocular Immunology and Inflammation, Vol. 29, Núm. 2, pp. 376-387

  2. Measuring Choroid Thickness as a Marker of Systemic Inflammation in Patients with Ankylosing Spondylitis

    Journal of Clinical Rheumatology, Vol. 27, Núm. 8, pp. E307-E311

2020

  1. Choroidal Thickness Is a Biomarker Associated With Response to Treatment in Ankylosing Spondylitis

    JCR: Journal of Clinical Rheumatology

2019

  1. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases

    Arthritis and Rheumatology, Vol. 71, Núm. 12, pp. 2081-2089

  2. Visual acuity loss and development of ocular complications in white dot syndromes: a longitudinal analysis of 3 centers

    Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 257, Núm. 11, pp. 2505-2516

2018

  1. Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease

    Ophthalmology, Vol. 125, Núm. 9, pp. 1444-1451

2017

  1. Development of an activity disease score in patients with uveitis (UVEDAI)

    Rheumatology International, Vol. 37, Núm. 4, pp. 647-656